LEADER 04394nam 22005654a 450 001 9910143429903321 005 20180718181636.0 010 $a1-280-23907-7 010 $a9786610239078 010 $a0-470-01161-0 010 $a0-470-01160-2 035 $a(CKB)1000000000354477 035 $a(EBL)239445 035 $a(OCoLC)475950703 035 $a(SSID)ssj0000257567 035 $a(PQKBManifestationID)11247170 035 $a(PQKBTitleCode)TC0000257567 035 $a(PQKBWorkID)10253977 035 $a(PQKB)10251030 035 $a(MiAaPQ)EBC239445 035 $a(EXLCZ)991000000000354477 100 $a20040625d2005 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $2rdacontent 182 $2rdamedia 183 $2rdacarrier 200 00$aTextbook of bone metastases$b[electronic resource] /$feditors, Claude Jasmin ... [et al.] 210 $aChichester ;$aHoboken, NJ $cJ. Wiley & Sons$dc2005 215 $a1 online resource (584 p.) 300 $aDescription based upon print version of record. 311 $a0-471-87742-5 320 $aIncludes bibliographical references and index. 327 $aTextbook of Bone Metastases; Contents; Contributors; Preface; Section 1 BIOLOGY OF BONE METASTASES; 1 General Mechanisms of Metastasis; 2 Parathyroid Hormone-related Protein and Bone Metastases; 3 Osteoblastic Metastases; 4 The Role of RANK, RANK Ligand and Osteoprotegerin in the Lytic Effects and Growth of Bone Metastases; Section 2 CLINICAL FEATURES AND ASSESSMENT; 5 Clinical Features and Prognosis of Bone Metastases; 6 Radioisotope and PET Imaging of Bone Metastases; 7 Imaging of Spinal Bone Metastases; 8 Monitoring Response to Treatment-the Role of Biochemical Markers 327 $a9 Surgical Biopsy of Bone MetastasesSection 3 SURGICAL TREATMENT; 10 Indications for the Surgical Treatment of Long Bone Metastases; 11 Prosthetic Replacement in Long Bone Metastases; 12 Osteosynthesis for Pathological Fractures in Long Bones; 13 Surgical Treatment of Pelvic Metastases; 14 Indications and Strategy for the Treatment of Spinal Metastases; 15 Surgical Techniques for the Treatment of Bone Metastases of the Spine; 16 Total En Bloc Spondylectomy for Spinal Metastases; Section 4 LOCAL TREATMENTS; 17 External Beam Radiation Therapy for the Treatment of Bone Metastases 327 $a18 Interventional Radiology for Bone Metastases19 Percutaneous Injection of Ethanol; Section 5 SYSTEMIC TREATMENTS; 20 Chemotherapy; 21 Endocrine Treatment of Bone Metastases; 22 Overview of Osteoclast Inhibitors; 23 Radioisotopes and Radioimmunoisotopes; 24 Immunotherapy; Section 6 BISPHOSPHONATES; 25 Mechanisms of Action of Bisphosphonates; 26 Antitumour Effects of Bisphosphonates; 27 Management of Hypercalcaemia; 28 Treatment of Lytic Bone Metastases; 29 Use in Multiple Myeloma; 30 Use in Prostate Cancer; 31 Prevention of Bone Metastases; 32 Prevention of Bone Loss 327 $a33 Cost Implications of BisphosphonatesSection 7 THE GLOBAL APPROACH; 34 Treatment of Bone Pain; 35 Specific Approaches to Cancer in the Elderly; 36 Psychological and Social Aspects; 37 Metabolic Bone Diseases in Childhood Cancer; Section 8 BONE METASTASES IN SPECIFIC TUMOURS; 38 Breast Cancer; 39 Prostate Cancer; 40 Multiple Myeloma; 41 Malignant Non-Hodgkin's Lymphoma; 42 Lung Cancer; 43 Kidney Cancer; 44 Evaluation of the Patient with Bone Metastases at Presentation; Index 330 $aThe epidemiological and clinical importance of bone metastases has long been recognised. For example, the incidence of bone metastases in breast and prostate cancers is 70%, whereas it is only 30 to 40% in metastatic lung cancer. In clinical terms, bone metastases have substantial negative effects on the patient's quality of life. Bone metastases have generally received insufficient attention because of the difficulty in quantifying them, which has left them outside the scope of therapeutic trials This textbook is the result of the remarkable progress made in the understanding of the molec 606 $aBone metastasis 608 $aElectronic books. 615 0$aBone metastasis. 676 $a616.99471 701 $aJasmin$b Claude$f1938-$0955843 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910143429903321 996 $aTextbook of bone metastases$92163505 997 $aUNINA